Evidence map›Paper›PMID 12848902›Full record

Trial reportBMC neurology2003

The Ischemic Stroke Genetics Study (ISGS) Protocol.

James F Meschia, Thomas G Brott, Robert D Brown, Richard J P Crook, Michael Frankel, John Hardy, José G Merino, Stephen S Rich, Scott Silliman, Bradford Burke Worrall and 1 more

Abstract readClinical TrialControlled Clinical TrialMulticenter Study
In one paragraph

Trial report in BMC neurology, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. NINDS stroke genetics network (SiGN) experience with the causative classification system.International journal of stroke : official journal of the International Stroke Society · 2013
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

James F MeschiaDepartment of Neurology, Mayo Clinic, Jacksonville, Florida, USA. Meschia.James@mayo.edu
Thomas G Brott
Robert D Brown
Richard J P Crook
Michael Frankel
John Hardy
José G Merino
Stephen S Rich
Scott Silliman
Bradford Burke Worrall
Ischemic Stroke Genetics Study

Funding

ISGS: The Ischemic Stroke Genetics StudyR01NS042733 · NINDS · MAYO CLINIC JACKSONVILLE · PI MESCHIA, JAMES F · 2002 to 2006
$3.7M
Genetics Of StrokeZ01AG000954 · NIA · NATIONAL INSTITUTE ON AGING · PI SINGLETON, ANDREW · 2002 to 2008
$831k
Genetics Of StrokeZIAAG000954 · NIA · NATIONAL INSTITUTE ON AGING · PI SINGLETON, ANDREW · 2009 to 2011
$815k
NINDS NIH HHS R01 NS-42733
6 · The paper itself

Abstract

backgroundThe molecular basis for the genetic risk of ischemic stroke is likely to be multigenic and influenced by environmental factors. Several small case-control studies have suggested associations between ischemic stroke and polymorphisms of genes that code for coagulation cascade proteins and platelet receptors. Our aim is to investigate potential associations between hemostatic gene polymorphisms and ischemic stroke, with particular emphasis on detailed characterization of the phenotype. METHODS/

designThe Ischemic Stroke Genetic Study is a prospective, multicenter genetic association study in adults with recent first-ever ischemic stroke confirmed with computed tomography or magnetic resonance imaging. Patients are evaluated at academic medical centers in the United States and compared with sex- and age-matched controls. Stroke subtypes are determined by central blinded adjudication using standardized, validated mechanistic and syndromic classification systems. The panel of genes to be tested for polymorphisms includes beta-fibrinogen and platelet glycoprotein Ia, Iba, and IIb/IIIa. Immortalized cell lines are created to allow for time- and cost-efficient testing of additional candidate genes in the future. DISCUSSION: The study is designed to minimize survival bias and to allow for exploring associations between specific polymorphisms and individual subtypes of ischemic stroke. The data set will also permit the study of genetic determinants of stroke outcome. Having cell lines will permit testing of future candidate risk factor genes.

Indexed as

Clinical ProtocolsAcademic Medical CentersAdultBrain IschemiaCase-Control StudiesCell LineFemaleFibrinogenFollow-Up StudiesGene Expression ProfilingHumansMalePlatelet Membrane GlycoproteinsPolymorphism, GeneticProspective StudiesReference ValuesFibrinogenPlatelet Membrane Glycoproteins

Identifiers

PMID12848902
PMCPMC184375

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.